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ABSTRACT
Objective: The present study is an attempt to investigate its anti-hyperlipidemic activity of methanolic extract of Syzygium alternifolium (MESA) using 
high-fat diet (HFDs) and dexamethasone-induced hyperlipidemia.
Methods: MESA bark was evaluated for anti-hyperlipidemic activity in HFD and dexamethasone-induced hyperlipidemic rats. A comparison was also 
made between the action of S. alternifolium bark extract and a known anti-hyperlipidemic drug atorvastatin (10 mg/kg body weight). The results of 
the study were expressed as mean ± standard error, and data were analyzed using one-way analysis of variance test followed by Dunnett’s t-test for 
multiple comparisons. Values of p<0.05 were considered as significant.
Results: Oral administration of 100, 200 mg/kg body weight of the MESA bark exhibited a significant reduction (p<0.01) in serum lipid parameters 
such as total cholesterol, triglycerides, low-density lipoprotein (LDL), very LDL, and increase in high-density lipoprotein in hyperlipidemic rats of both 
models as compared to hyperlipidemic control statistically. These extracts were found to possess better anti-hyperlipidemic potential.
Conclusion: Our results demonstrated that MESA bark possessed significant anti-hyperlipidemic activity and hence it could be a potential herbal 
medicine as an adjuvant with existing therapy for the treatment of hyperlipidemia.
Keywords: Syzygium alternifolium, Hyperlipidemia, High-fat diet, Dexamethasone.
INTRODUCTION
In 2002 cardiovascular diseases (CVD’s) contributed to approximately 
a third of entire global deaths, whereas by the year 2020. It is expected 
that CVD’s will become the leading cause of death and disability 
worldwide [1]. Hyperlipidemia is a major cause of atherosclerosis and 
atherosclerosis - Associated conditions such as coronary heart diseases 
(CHD), ischemic cerebrovascular disease, and peripheral vascular 
diseases [2].
Atherosclerosis referred to as a “silent killer” is one of the leading causes 
of death in the developed countries and is on the rise in developing 
countries like India [3]. The American Heart Association has identified 
the primary risk factor associated with atherosclerosis as elevated 
levels of cholesterol and triglycerides (TG) in the blood. Therefore, 
therapists consider the treatment of hyperlipidemia to be one of the 
major approaches toward decelerating the atherogenic process [4]. 
Allopathic hypolipidemic drugs are available at large in the market, but 
the side effects and contraindications of these drugs have masked their 
popularity. Recently, herbal hypolipidemics have to gain importance to 
fill the lacunae created by the allopathic drugs [5].
Herbal medicine represents one of the most important fields 
of traditional medicine. WHO recognized that medicinal plants 
played an important role in the health care of about 80% of the 
world population in developing countries and depended largely on 
traditional medicine [6]. Plant derived products are present in 14 of 
the 15 therapeutic categories of pharmaceutical preparations that are 
currently recommended by medicinal practitioners, and they form an 
important part of the health care system in the western world [7]. It is 
estimated that about 75% of the 120 biologically active plant-derived 
compounds, presently in use worldwide, have been derived through 
follow-up researchers to verify the authenticity of data from folk and 
ethnomedicinal uses. So, there is a great scope for new drug discoveries 
based on traditional plant uses [8]. There is a need to establish the 
pharmacological activities for identifying and comparing the various 
crude drugs for potency.
Syzygium alternifolium (Wt.) Walp. (Myrtaceae) is an endemic aromatic 
tree, distributed in Assam and Andhra Pradesh, states of India. Locally, 
it is known as mogi/movi. The plant parts were used in traditional 
medicine to cure various diseases viz., tender shoots and fruits for 
dysentery, seeds for diabetes and stem bark was used to treat gastric 
ulcers [9]. The anti-hyperlipidemic effects of methanolic extract of 
S. alternifolium (Wt.) Walp (MESA) bark against high-fat diet (HFD) 
and dexamethasone-induced hyperlipidemia in rats have not been 
reported so far scientifically. Hence, the present study has been carried 
out to evaluate the anti-hyperlipidemic effect of MESA against HFD and 
dexamethasone-induced hyperlipidemia in rats.
METHODS
Plant materials
S. alternifolium (Wt.) Walp plant bark was collected in the month of 
November 2014 from Sheshachalam hills, Tirupati, Andhra Pradesh, 
India. The plant was then taxonomically identified and authenticated by 
the botanist Dr. K. Madhava Chetty, Assistant Professor in S.V. University, 
Tirupati, India.
Preparation of extract
The bark was dried under shade then coarsely powdered with a 
mechanical grinder. The powder was passed through a sieve and stored 
in an airtight container for the extraction, and Extracted with methanol 
70% (75-78°C) up to 72 hrs. After completion of extraction, the solvent 
was removed by distillation. Dark brown residue was obtained. The 
residue was concentrated and then stored in desiccators [10].
Preliminary phytochemical screening
The extracts were subjected to phytochemical investigation for plant 
secondary metabolites such as alkaloids, tannins, flavonoids, glycosides, 
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saponins, carbohydrates, phenolic compounds, fixed oils, terpenoids, 
and steroids by utilizing standard methods [11].
Experimental animals
Wistar rats (150-180 g) of either sex approximately the same age, 
procured from listed suppliers of Albino labs, Hyderabad, India were 
used for the study. They were housed in polypropylene cages and fed 
with standard rodent pellet diet and water ad libitum. The animals were 
exposed to an alternate cycle of 12 hrs of darkness and 12 hrs of light. 
All the experimental works with the animals were carried out after 
obtaining approval from the Institutional Animal Ethics Committee 
(Reg. No. 1175/ac/08/CPCSEA).
Acute toxicity studies
An acute oral toxicity study was performed as per Organization for 
Economic Co-operation and Development 423 guidelines (acute toxic 
class method). Wistar rats (n=6) of either sex selected by random 
sampling technique were used for the study. The animals were kept 
fasting for overnight providing only water, after which the extracts were 
administered orally at the dose level of 5 mg/kg body weight (b.w.) by 
intragastric tube and observed for 14 days. If mortality was observed in 
2-3 animals, then the same dose was observed in one animal, and then 
the same dose was repeated again to confirm the toxic dose. If mortality 
was not observed, the procedure was repeated for further higher dose 
such as 50, 300, and 2000 mg/kg b.w. [12].
Experimental design
Anti-hyperlipidemic activity
Anti-hyperlipidemic activity animals were divided into five groups with 
six animals per group.
Group 1: Normal control.
Group 2: Hyperlipidemic control (Vehicle 1 ml/100g/day p.o).
Group 3:  Hyperlipidemic treated with MESA bark (100 mg/kg, 
b.w./day p.o).
Group 4:  Hyperlipidemic treated with MESA bark (200 mg/kg, 
b.w./day p.o).
Group 5:  Hyperlipidemic treated with atorvastatin (10 mg/kg, 
b.w./day p.o).
The animals were administered with corresponding treatment for 
1 month.
Induction of hyperlipidemia
High cholesterol diet was prepared by mixing cholesterol 2%, sodium 
cholate 1%, and coconut oil 2%, with powdered standard animal 
food [2,13]. The diet which was prepared as pellets was placed in the 
cage carefully and was administered for 20 days.
Dexamethasone-induced hyperlipidemia in rats
To induce hyperlipidemia by using dexamethasone, (a glucocorticoid 
excess is known to evoke plasma lipid elevation) dexamethasone 
(10 mg/kg/day, s.c) was administered to rats for 8 days to induce 
hyperlipidemia. The animals were divided into five groups each group 
contains six rats. After the induction of hyperlipidemia, MESA was given 
to the rats for 8 days in the dose of 100 mg/kg and 200 mg/kg, on 9th day 
blood was collected from retro-orbital plexus, after overnight fasting for 
the study of biochemical parameters.
Group1: Normal control.
Group 2: Dexamethasone control (Vehicle 1 ml/100 g/day p.o).
Group 3:  Dexamethasone (10 mg/kg/day, s.c) + MESA bark (100 mg/kg, 
b.w./day p.o).
Group 4:  Dexamethasone (10 mg/kg/day, s.c) + MESA bark (200 mg/kg, 
b.w./day p.o).
Group 5:  Dexamethasone (10 mg/kg/day, s.c) + Atorvastatin (10 mg/kg, 
b.w./day p.o).
Biochemical assays for lipids
Total cholesterol estimation was done by using the span total cholesterol 
diagnostic kit. Serum TGs and high-density lipoproteins (HDL) were 
estimated by span TGs diagnostic kit. Cholesterol, TGs, and HDL profile 
were estimated using standard monograph. Low-density lipoproteins 
(LDL) cholesterol was calculated using formula:
LDL = Total cholesterol−HDL−TGs/5
Very LDLs (VLDL) was calculated using the formula:
VLDL=TGs/5.
The liver was fixed in 10% formalin for histopathological studies.
Measurement of coronary disease risk factor
Atherogenic index (AI), which is a measure of the atherogenic potential 
of an agent, was calculated using the following formula, and the results 
were tabulated.
AI = LDL-cholesterol/HDL-cholesterol
% Protection = AI of control - AI of treated group × 100 AI of control
In vivo antioxidant studies
Antioxidant studies are performed using determination of superoxide 
scavenging activity, lipid peroxidation (LPO) assay, glutathione 
(GSH) assay, and catalase activity [14]. The results were shown in 
Tables 4 and 5.
Histopathological studies
A portion of liver tissue (liver slices) of normal control, 
dexamethasone control, cholesterol control, and co-treated groups of 
rats with atorvastatin and MESA (100 mg/kg) and MESA (200 mg/
kg) were stored in containers for 12 hrs in 10% formalin solution and 
subjected to histopathological studies [15]. Observed microscopically 
for histopathological changes, i.e., normal liver, damaged and 
recovered liver was studied and compared. The results were shown 
in Fig. 1.
Statistical analysis
All the values were expressed as mean ± standard error of mean. 
The datas were statistically analyzed by one-way analysis of variance 




Administration of S. alternifolium bark extracts in the doses of 50, 300, 
and 2000 mg/kg resulted in no mortalities or evidence of adverse 
effects implying that S. alternifolium is non-toxic. Throughout 14 days of 
the treatment, no changes in behavioral pattern, clinical signs and body 
weight of mice in both control and treatment groups were observed. 
This shows that S. alternifolium was safe up to a dose of 2000 mg/kg.
Preliminary phytochemical screening
Preliminary phytochemical screening was done and found the presence 
of steroids, terpenoids, flavonoids, alkaloids, phenolic compounds, 
saponins, tanins and carbohydrates. The results were given below in 
Table 1.
Anti-hyperlipidemic activity
When MESA was evaluated for its anti-hyperlipidemic activity against 
HFD and dexamethasone-induced hyperlipidemia model, it showed a 
statistically significant activity in dose of 100 mg/kg and 200 mg/kg 
by oral administration. After 21 days, HFD and 8 days treatment with 
dexamethasone, a significant rise in lipid and lipoprotein levels were 
observed in serum in dexamethasone-induced group, when compared 
to the normal group. The results were depicted in Tables 2 and 3.
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In vivo antioxidant studies
In vivo antioxidant studies showed that superoxide dismutase (SOD), 
GSH, and catalase levels have increased and LPO levels decreased in the 
groups treated with extracts. The results were shown in Tables 4 and 5.
Histopathology
The histopathological study showed recovery of the damaged liver cells 
in the drug treated group. The reputed cells of the intoxicated liver were 
reformed. The degree of vascularization was also reduced as compare to the 
hyperlipidemic group. Multiple foci of inflammation and necrosis noticed 
in centrilobular region of liver, Furthermore, infiltration of inflammatory 
cells noticed in the inflammatory region of liver. In HFD model mild to 
moderate sinusoidal space dilatation along with hemorrhages noticed in 
the sinusoidal space of liver and multiple foci of inflammation along with 
infiltration of inflammatory cells particularly lymphocytes noticed in the 
centrilobular region of liver. The results were shown in Fig. 1.
DISCUSSION
The present studies were performed to assess the anti-hyperlipidemic 
activity and to prove its claim in folklore practice against various 
Table 1: Phytochemical investigation of 
Syzygium alternifolium (wt.) Walp bark methanolic extract




4 Saponins and flavonoids ++
5 Tannins and phenolic compounds ++
+: Presence of constituents
Table 5: In vivo antioxidant studies in dexamethasone-induced hyperlipidemia
Groups SOD (U/mg of protein) GSH (μM/min/mg of protein) Catalase (μM/mg of protein) LPO (nM MDA/g of protein)
I 9.6±0.1 10±0.05 12.68±0.19 5.3±0.05
II 1.68±0.23a 1.78±0.04a 1.18±0.04a 15.93±0.05a
III 5.6±0.21a,**,A 4.45±0.13a,**,A 5.15±0.05a,**,A 12.3±0.18a,**,A
IV 6.4±0.13a,*,A 6.3±0.18a,*,A 7.18±0.07a,**,A 10.8±0.04a,**,A
V 7.7±0.11b,** 8.51±0.08b,** 10.25±0.095b,** 7.26±0.06b,**
Values are expressed as mean±SEM, (n=6). All the groups were compared with control group and standard group. All the data were statistically analyzed by one-way 
ANOVA followed by Dunnett’s test, and Significant values are expressed as ap<0.001, bp<0.05, **p<0.01, *p<0.05, standard (A=p<0.01, B=p<0.05). ns: Non-significant, 
SOD: Superoxide dismutase, GSH: Glutathione, LPO: Lipid peroxidation, HFD: High-fat diet, SEM: Standard error of mean
Table 4: In vivo antioxidant studies in HFD induced hyperlipidemia
Groups SOD (U/mg of protein) GSH (μM/min/mg of protein) Catalase (μM/mg of protein) LPO (nM MDA/g of protein)
I 9.4±0.1 9.35±0.08 10.48±0.2 6.15±0.09
II 2.1±0.1a 1.2±0.05a 1.16±0.04a 14.97±0.08a
III 4.86±0.1a,**,A 4.45±0.13a,**,A 3.45±0.07a,**,A 11.53±0.09a,**,A
IV 6.26±0.21a,*,A 6.3±0.12a,**,B 5.71±0.06a,**,A 9.76±0.03a,**,A
V 7.8±0.08b,** 7.8±0.05b,** 8.9±0.13b,** 7.31±0.04b,**
Values are expressed as mean±SEM, (n=6). All the groups were compared with control group and standard group. All the data were statistically analyzed by one-way 
ANOVA followed by Dunnett’s test andSignificant values are expressed as ap<0.001, bp<0.05, **p<0.01, *p<0.05, standard (A=p<0.01, B=p<0.05). ns: Non-significant, 
SOD: Superoxide dismutase, GSH: Glutathione, LPO: Lipid peroxidation, HFD: High-fat diet, SEM: Standard error of mean
Table 2: Effect of MESA bark on HFD induced hyperlipidemia
Groups Treatment TC mg/dl TG mg/dl LDL mg/dl VLDL mg/dl HDL mg/dl AI mg/dl
I Control 102.3±1.9 79.8±1.6 37.7±2.3 15.8±0.3 46.83±2.1 1.7±0.06
II Cholesterol control 219.6±11.1a 185.5±6.9a 162.9±11a 30.3±1.1a 26.33±0.6a 5.9±0.3a
III MESA 100 mg/kg 131.6±2.7a,**,A 129±1.6a,**,B 63.3±2.8b,**,A 25.8±0.3a,**,A 41.33±0.3b,**,A 1.5±0.1a,**,B
IV MESA 200 mg/kg 116.6±1.7a,**,B 109±1.54a,*,B 48.7±1.6a,**,B 21.6±0.2a,*,B 43.8±0.9b,**,B 1.1±0.5a,**,B
V Atorvastatin 10 mg/kg 110.3±3.4b,** 104.1±5.3b,** 46.5±4.0b,** 20.83±1.0b,** 47.5±0.4b,** 0.9±0.1b,**
Values are expressed as mean±SEM, (n=6). All the groups were compared with control group and standard group. All the data were statistically analyzed by one-way 
ANOVA followed by Dunnett’s test, and significant values are expressed as ap<0.001, bp<0.05, **p<0.01, *p<0.05, A: p<0.01, B: p<0.05. ns: Non-significant. TC: Total 
cholesterol, TG: Triglyceride, LDL: Low-density lipoprotein, HDL: High-density lipoproteins, AI: Atherogenic index, MESA: Methanolic extract of Syzygium alternifolium, 
HFD: High-fat diet, SEM: Standard error of mean
Table 3: Effect of MESA in dexamethasone-induced hyperlipidemia
Groups Treatment TC mg/dl TG mg/dl LDL mg/dl VLDL mg/dl HDL mg/dl AI mg/dl
I Control 103.83±2.8 77.5±2.078 42.6±2.8 15.5±0.4 47.83±2.4 0.89±0.06
II Cholesterol control 212.5±10.2a 173.1±12.9a 150.1±12a 34.6±2.5a 27.5±0.8a 5.49±0.48a
III MESA 100 mg/kg 127.3±2.4b,**,B 124.3±3.4a,**,B 59.3±2.04a,**,B 24.8±0.6a,**,B 43.1±0.9a,**,A 1.37±0.04a,**,B
IV MESA 200 mg/kg 113.8±1.3a,**,A 117.5±3.4a,*,B 42.8±1.7a,**,B 23.5±0.6a,*,B 47.5±0.5a,**,A 0.9±0.04a,**,B
V Atorvastatin 10 mg/kg 103±1.06b,** 99.6±2.17b,** 33.3±1.07b,** 19.9±0.4b,** 49.6±0.7b,** 0.66±0.02b,**
Values are expressed as mean±SEM, (n=6). All the groups were compared with control group and standard group. All the data were statistically analyzed by one-way 
ANOVA followed by Dunnett’s test and Significant values are expressed as ap<0.001, bp<0.05, **p<0.01, *p<0.05, standard (A=p<0.01, B=p<0.05),. ns: Non-significant, 
MESA: Methanolic extract of Syzygium alternifolium, TC: Total cholesterol, TG: Triglyceride, LDL: Low-density lipoprotein, VLDL: Very low-density lipoprotein, 
HDL: High-density lipoproteins, AI: Atherogenic index
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disorders. Cholesterol is synthesized in all animal tissue. It’s important 
relates to its role in the stabilization of membrane structures because of 
its rigid planar structure. Increased amount of cholesterol leads to CVD 
particularly CHD [17].
The plasma cholesterol was reduced remarkably on treating the HFD 
rats with methanol extract of S. alternifolium. The lipid lowering effects 
may be due to the presence of plant sterol. Plant sterol reduces the 
absorption of cholesterol and thus increases the fecal excretion of 
steroids that results in decrease of body lipids reduction 1% cholesterol 
produces a 2-3% reduction in CHD risk [18].
The excess of fat diet increased the TG level which is one of the causes 
of hardening of arteries. HDL is known as the good cholesterol it has 
reversed the transport function. It carries cholesterol away from the 
including the coronary categories and drops it off at the liver. HDL is 
directly anti-androgenic, and it is believed to remove cholesterol from 
the developing lesions.
LDL is a risk factor and plays a role at several steps of atherosclerosis. 
A decrease in oxidative stress and protection of LDL from oxidation 
might, therefore, be a strategy with great promise for prevention of 
atherosclerosis associated CVD. VLDL production is directly related 
to the body fat. Severe elevation in the VLDL cholesterol leads to 
hypercholesterolemia. TGs are mainly stored in the adipose tissue. 
The plasma lipoproteins are major sources of fatty acid to synthesis 
triacylglycerol. The excess of fat diet increased the TG level which is one 
of the causes of hardening of arteries [19].
It has been reported that HFD brings about remarkable modifications 
in the antioxidant defense mechanisms of rat tissues by increasing 
the process of LPO, which plays an important role in oxidative 
stress of biological systems [20]. In the present study, MESA bark 
showed highly significant reduction in LPO levels compared to HFD 
group. This effect can be attributed to the phenolic constituents in S. 
alternifolium bark which has the ability to strongly inhibit LPO and 
high concentration of flavonoids which are potent antioxidants, lead 
to increase in antioxidant enzymes such as SOD, catalase, and GSH 
levels (Tables 4 and 5) and finally histopathology study supports the 
same in Fig. 1.
The preliminary phytochemical studies identified the presence of 
alkaloids, glycosides, terpenoids, steroids, flavonoids, volatile oils, 
tannins, proteins, and carbohydrates in MESA.
It is reported that phytosterol is useful in the treatment of 
hyperlipidemia [21]. Phenolic constituents have the ability to strongly 
inhibit the LPO process, and flavonoids act as potent antioxidants and 
free radical scavengers [22]. Phytosterols, triterpenoids, flavonoids, 
tannins, and phenolic constituents in MESA might be responsible for 
the hypolipidemic activity. Further experiments are required to prove 
the mechanism and advantage of S. alternifolium (Wt.) Walp (MESA) 
over other drugs.
CONCLUSION
These results suggested that MESA possess significant anti-
hyperlipidemic activity.
REFERENCES
1. Ankur R, Nidhi D, Seema R, Amarjeet D, Ashok K. Hyperlipidemia - A 
deadly pathological condition. Int J Curr Pharm Res 2012;4(2):15-8.
2. Begum S, Aslama M. Lipid lowering activity of fruits of Carum carvi 
Linn in cholesterol and triton fed hyperlipidemic rats. Int PharmSci 
2012;2(2):103-7.
3. Ghatak A, Asthana OP. Recent trends in hyperlipoproteinemias and its 
pharmacotherapy. Indian J Pharmacol 1995;27:14-29.
4. Moss JN, Dajani E. Antihyperlipidemic agents. In: Turner RA, 
Hebborn P, editors. Screening Methods of Toxicology. Vol II. New York: 
Academic Press; 1971. p. 121.
5. Anonymous. Drug Index. New Delhi: Pass Publication Pvt. Ltd.; 1999. 
p. 482.
6. Fransworth NR, Akerele O, Bingel AS, Soejarto DD, Guo ZG. 
Medicinal plants in therapy. Bull World Health Organ 1985;63:965-81.
7. Phillipson JD, Anderson LA. Ethnopharmacology and Western 
medicine. J Ethnopharmacol. 1989;25(1):61-72.
8. Pushpangadan P, Kumar B. Ethnobotany, CBD, WTO and the 
biodiversity act of India. Ethnobotany 2005;17:2-12.
9. Suvarchala Reddy NV, Kusuma Priyanka AY. Isolation and 
characterization of triterpenoids from bark of Syzygium alternifolium 
(wight) walp. Ann Phytomed 2012;1(2):45-51.
10. Sudhakar A, Ramesh C, Nagaraju N, Vedavaty S, Murthy SK. 
Pharmacognostic Studies on Stem & Fruit of Syzygium alternifolium 
(Wight) Walp., An Endemic to South Eastern Ghats, India. Asian J 
Biochem Pharma Res 2012;2(1):127-38.
11. Bharathi T, Siddaiah M, Sriharsha SN. Anti-inflammatory activity of 
methanol extract of Syzygium alternifolium in experimental rats. Int J 
Innov Pharma Res 2012;3(4):255-7.
12. Sastry SP, Kuppast IJ. Evaluation of antihyperlipidemic activity 
of leaves of Portulaca oleracea Linn in rats. Int J Pharm Pharm Sci 
2012;4(4):279-83.
13. Alam NM, Bristi NJ, Uzzaman RM. Review on in vivo and 
in vitro methods evaluation of antioxidant activity. Saudi Pharm J 
2013;21:143-52.
14. Al-Awadi JH, Rashid KH, Hassen AJ. High fat diet induces 
hyperlipidemia incidences with sever changes in liver tissue of male 
albino rats: A histological and biochemical study. Kerbala J Pharma Sci 
2013;6:21-32.
15. Haughton PJ, Raman A. In: Laboratory Handbook for the Fractionation 
of Natural Extracts. 1st ed. USA: Clapman and Hall; 1998. p. 22-52.
16. Berteri AR. Risk of coronary artery heart diseases. Health Screen 
2003;1:28-9.
17. Sowmya A, Ananthi T. Hypolipidemic activity of Mimosa pudica 
Linn on butter induced hyperlipidemia in rats. Asian J Res Pharm Sci 
2011;1(4):123-6.
18. Xu Y, He Z, King GL. Introduction of hyperglycemia and dyslipidemia 
in the pathogenesis of diabetic vascularcomplications. Curr Diabetes 
Rep 2005;5(2):91-7.
19. Kesavulu M, Kemeshwara M, Rao B, Giri R. Lipid peroxidation and 
antioxidant enzyme status in type to diabetics with coronary heart 
disease. Diabetes Res Clin Pract 2001;1(53):33-9.
20. Bopanna KN, Bhagyalakshmi N, Rathod SP, Balaraman R, Kannan J. 
Cell culture derived Hemidesmus indicus in the prevention of 
hypercholesterolemia in normal and hyperlipidemic rats. Indian J 
Pharmacol 1997;29:105-6.
21. Sudhessh S, Vijay KS, Sandhya C, Vijayalakshmi NR. Toxic effects 
of condensed tannins from Solanum melongenon on rats. J Ecotoxicol 
Environ Monit 1996;6:221-8.
22. Theeshan B, Neergheen VS, Aruoma OI. Phytochemical constituents of 
Cassia fistula. Afr J Biotechnol 2005;4(13):1530-40.
Fig. 1: Histopathology (liver) of high-fat diet (HFD) induced 
hyperlipidemia model, (a) Normal, (b) HFD induced, 
(c) methanolic extract of Syzygium alternifolium (MESA) 
100 mg/kg, (d) MESA 200 mg/kg, HFD + standard (atorvastatin) 
10 mg/kg
dc
ba
e
